These results demonstrate that HMGB1 serves as a powerful bridge between progressive dopaminergic neurodegeneration and chronic neuroinflammation in PD, suggesting that HMGB1 is a suitable target for neuroprotective trials in PD. This evidence concerns the gene HMGB1 and Parkinson disease.